Document Detail


The current status of engineering myocardial tissue.
MedLine Citation:
PMID:  20198517     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Myocardial infarction (MI) remains a common fatal disease all over the world. The adult cardiac myocytes regenerative capability is very limited after infarct injury. Heart transplantation would be the best therapeutic option currently but is restricted due to the lack of donor organs and the serious side effects of immune suppression. The emerging of tissue engineering has evolved to provide solutions to tissue repair and replacement. Engineering myocardial tissue is considered to be a new therapeutic approach to repair infarcted myocardium and ameliorate cardiac function after MI. Engineering myocardial tissue is the combination of biodegradable scaffolds with viable cells and has made much progress in the experimental phase. However, the largest challenge of this field is the revascularization of the engineering constructs to provide oxygen and nutrients for cells. This review will give an overview on the current evolution of engineering myocardial tissue and address a new method to improve the vascularization of myocardium tissue in vivo.
Authors:
Runqian Sui; Xiaobo Liao; Xinmin Zhou; Qi Tan
Related Documents :
18577527 - Adenovirus-mediated stromal cell-derived- factor-1alpha gene transfer induces cardiac p...
11390337 - Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therap...
21071717 - Wnt signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac...
19699857 - Rationale and design for time: a phase ii, randomized, double-blind, placebo-controlled...
9323077 - Predictors of arrhythmic death and cardiac arrest in the esvem trial. electrophysiologi...
2346957 - Improved cardiac performance with human calcitonin gene related peptide in patients wit...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Stem cell reviews     Volume:  7     ISSN:  1558-6804     ISO Abbreviation:  Stem Cell Rev     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-01-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101255952     Medline TA:  Stem Cell Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  172-80     Citation Subset:  IM    
Affiliation:
Department of Cardiothoracic Surgery, Xiangya Second Hospital, Central South University, Changsha, Hunan, 410011, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stem Cell Research in the Greater Middle East: The Importance of Establishing Policy and Ethics Inte...
Next Document:  Human bone marrow mesenchymal stem cells: a systematic reappraisal via the genostem experience.